had its stock upgraded to Good from Above Average by Sadif Investment Analytics, the research firm reported in a rating update note.
The Canadian health technology company "has a bright prospect with an overall score of 87/100" (100 being the highest), Sadif wrote. "Overall, we expect Reliq to be a good long-term investment that is likely to deliver long-term returns."
The total score reflects how Reliq fared since its last rating in a dozen categories, as determined using the Summary StockMarks rating system, versus the entire population of 2,193 Canada-listed companies rated today. The current scores are based on data as of the market close on May 24, 2023.
Reasons for the Uprating
Sadif ascribed the improved overall performance and, thus, upgraded the rating to improvements in Reliq's business market sentiment and in its technicals (79%). Current investor sentiment toward the healthcare technology firm is "bullish and with a positive outlook," Sadif described. Analyst consensus about Reliq is positive, too.
Also working in Reliq's favor are fair financials, good earnings quality, low information risk, and acceptable market risk. Operational risk is average.
When compared to its closest competitor, Playmaker Capital Inc. (PMKR:TSX.V; PMKRF:OTCQX), Reliq shows greater undervaluation and is equally likely to outperform the market.
|Want to be the first to know about interesting Healthcare Services investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter.||Subscribe|
1) Reliq Health Technologies Inc. is a billboard sponsor(s) of Streetwise Reports and has paid SWR a sponsorship fee between US$3,000 and US$5,000.
2) Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
5) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
Disclosures for Sadif Research, Reliq Health Technologies Inc., May 24, 2023
© 2007-2023 Marques Mendes & Associados Lda (MM&A). All Rights Reserved. This report is for information purposes only and is not a solicitation or advice to buy or sell any security. The data contained within this report is not warranted to be accurate or complete. This report is only intended as a summary of SADIF's stock ratings and not a recommendation for stock purchase or sale. Redistribution of this report without explicit permission is strictly prohibited. All logos are the copyright property of their respective companies and are used here only to aid the reader in identification of the subject of the article. The author of this article does not hold a position in any of the companies featured within this report.